Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
Chiasma, Inc. stock logo
CHMA
Chiasma
$3.76
$4.01
$2.77
$5.74
$217.68M1.282.12 million shs147 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$13.08
+3.1%
$12.51
$5.22
$27.38
$159.74M0.43153,968 shs173,279 shs
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$3.81
-1.6%
$3.32
$1.94
$5.65
$204.30M0.36372,023 shs284,831 shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$7.40
+1.1%
$7.38
$3.34
$16.50
$20.39M1.132,957 shs1,146 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00%0.00%0.00%0.00%0.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+1.28%-1.48%-12.96%+97.66%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
0.00%+0.78%+9.32%+47.15%-11.03%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
0.00%-1.48%-0.27%+33.58%-17.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.029 of 5 stars
3.50.01.72.72.61.71.3
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.5827 of 5 stars
3.54.00.04.23.81.70.6
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
2.6507 of 5 stars
3.53.00.00.02.21.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera AG stock logo
BFRA
Biofrontera
0.00
N/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
0.00
N/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50133.18% Upside
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.00
Buy$14.00267.45% Upside
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.00
Buy$40.00440.54% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
Chiasma, Inc. stock logo
CHMA
Chiasma
$1.11M196.11N/AN/A$1.59 per share2.36
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.82$0.91 per share14.39$2.05 per share6.38
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
$36.33M5.54N/AN/A$0.27 per share14.11
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$11.54M1.79N/AN/A$10.36 per share0.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
Chiasma, Inc. stock logo
CHMA
Chiasma
-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.96N/A4.12%34.67%15.24%8/27/2025 (Estimated)
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$85.15M-$1.91N/AN/AN/A-216.24%-594.07%-73.54%8/13/2025 (Estimated)
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)

Latest LFVN, SCPH, BFRA, SLGL, and CHMA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/23/2025Q1 2025
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A-$3.20N/A-$3.20N/A$1.03 million
5/14/2025Q1 2025
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
-$0.28-$0.34-$0.06-$0.37$11.63 million$11.75 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
Chiasma, Inc. stock logo
CHMA
Chiasma
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.38%N/A26.09%3 Years
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
N/AN/AN/AN/AN/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A

Latest LFVN, SCPH, BFRA, SLGL, and CHMA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
Chiasma, Inc. stock logo
CHMA
Chiasma
N/A
7.91
7.08
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3.86
5.48
4.61
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
5.12
5.12

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
Chiasma, Inc. stock logo
CHMA
Chiasma
61.68%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
89.52%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
26.18%

Insider Ownership

CompanyInsider Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
N/A
Chiasma, Inc. stock logo
CHMA
Chiasma
8.30%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
4.78%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
66.51%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
Chiasma, Inc. stock logo
CHMA
Chiasma
8557.89 millionN/ANot Optionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
scPharmaceuticals, Inc. stock logo
SCPH
scPharmaceuticals
3052.79 million50.27 millionOptionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
502.79 million933,000Optionable

Recent News About These Companies

SLGL Sol-Gel Technologies Ltd. - Seeking Alpha
Sol-Gel Technologies Ltd
Sol Gel Tech Stock Price History
Sol-Gel Reports First Quarter 2025 Results
Sol-Gel Announces Reverse Share Split
Sol-Gel, Mayne Pharma enter product purchase agreement
Sol Gel Technologies Ltd (SLGL) Stock Trading Recap
Sol-Gel Technologies Reports Strong Q3 2024 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Chiasma stock logo

Chiasma NASDAQ:CHMA

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$13.08 +0.39 (+3.07%)
As of 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

scPharmaceuticals stock logo

scPharmaceuticals NASDAQ:SCPH

$3.81 -0.06 (-1.55%)
As of 04:00 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Sol-Gel Technologies stock logo

Sol-Gel Technologies NASDAQ:SLGL

$7.40 +0.08 (+1.09%)
As of 02:34 PM Eastern

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.